Autres langues Evolus, Inc.

Actions

EOLS

US30052C1071

Temps réel estimé Cboe BZX Autres places de cotation 17:32:47 26/04/2024			Varia. 5j.	Varia. 1 janv.
11,4 ^USD	-0,52 %		-0,95 %	+8,45 %

13:36	AbbVie relève ses prévisions de bénéfices annuels en raison des fortes ventes de Skyrizi	RE
17/04	Evolus, Inc. annonce la publication des données de sécurité et de durée de l'étude de phase 2 pour la formulation 40U "extra forte" de Jeuveau	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

AbbVie raises annual profit forecast on strong Skyrizi sales	13:36
Evolus to Report First Quarter Financial Results on May 7, 2024	23/04
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®	17/04
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau	17/04
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	15/04
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	12/04
Evolus, Inc. Announces Board Changes	03/04
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference	26/03
Evolus Insider Sold Shares Worth $1,344,604, According to a Recent SEC Filing	22/03
Evolus Prices $50 Million Share Offering	11/03
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	11/03
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock	11/03
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Sector Update: Health Care Stocks Steady Pre-Bell Friday	08/03
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results, Reaffirms 2024 Guidance	08/03
Evolus Q4 Net Loss Narrows, Revenue Increases; 2024 Revenue Guidance Affirmed; Shares Fall After Hours	07/03
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (EOLS) EVOLUS Posts Q4 Revenue $61M, vs. Street Est of $61.1M	07/03
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance	07/03
Evolus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Evolus, Inc.

Actions

EOLS

US30052C1071

Autres langues

Filtres